Brightline DX’s Claritas platform to be used to rule out heart attacks for Stream Bio’s SBRI-funded project


May 10, 2021 2:52 pm

Brightline Diagnostics (DX) is delighted to announce that co-founding company Stream Bio has won funding from SBRI Healthcare’s ‘Urgent and Emergency Care’ competition to develop a lateral flow assay for bioindicators of heart attacks. The Claritas diagnostic system, developed in close collaboration with fellow Brightline DX co-founder Chelsea Technologies, will be used as a final test platform. The outcomes of this project could improve emergency care for heart attack patients dramatically.

Suspected heart attacks, or myocardial infarctions (MI), place a significant strain on healthcare services. Of the average 1.24 million chest pain admissions a year, only approximately 20% will be diagnosed as heart attacks. This results in unnecessary admissions of non-heart attack cases until lab-based tests can finally rule out MI, costing the NHS more than £170 million each year. A high-sensitivity troponin point-of-care lateral flow test would improve efficiency within the NHS, reduce costs, enable earlier interventions and reduce the number of unnecessary hospital admissions.

Stream Bio aims to address this need with a novel, highly sensitive diagnostic platform. The platform will use Stream Bio’s intensely bright and sensitive fluorescent nanotechnology – Conjugated Polymer Nanoparticles (CPNs™) – in a lateral flow assay to detect cardiac troponin I and T, high levels of which can indicate MI.

In collaboration with Stream Bio, Chelsea Technologies has developed a novel fluorometric reader as part of Brightline DX’s combined system named Claritas, which will be used to accurately and sensitively interpret the lateral flow assay for MI. The reader is handheld, battery-powered and robust, making it ideal for use in an ambulance and emergency room setting.

This announcement represents another significant step forward for the application of Brightline DX’s Claritas diagnostic system. In addition to MI-related healthcare challenges, Brightline has been focusing on developing a highly sensitive saliva-based rapid test for COVID-19. Plans to apply the novel technology to a wide range of diagnostic targets are already in the pipeline.